Descripción: |
Biomedical research ethics is a hot topic in USA today as it used to
be when it was born three decades ago. New procedures to preserve
and protect the scientific integrity and the human subjects involved in
clinical trials are the response to the increasing distrust in scientific
protocols, which some times do not follow the orthodox ethical
standards, and many a times have developed some harm to
participants becoming a threat to national human research policies.
The new scene of investigation associates both the academic
knowledge and the private enterprise; though not a novelty it shows
now an exceptional financial increment by the pharmaceutical and
biotechnological industries. In this sense, the industry changes the
financial support from the academic to the private medicine -of a
profitable nature- grounded on intermediary organizations that
manage clinical trials providing the access to hospitals, health
professionals, and patients.
The concern then lies on this approach to managing clinical trials
as long as investigation quality and human subjects are involved,
mainly as regards the conflict of economical interests that arise among
professionals and "non institutional" revision committee members. The
consequence is a proposal of new rules for the handling of those
conflicts of interests and the encouragement of education in bioethics
for clinical researchers and revision committee s members. Trabajo presentado al VI Congreso Mundial de Bioética, Brasilia, Brasil, 30 de octubre al 3 de noviembre de 2002 |